Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling
Open accessThe DOI matches its Crossref record; 127 of the 143 references it cites were found in a registry or an index; 5 of the 101 sources its claims cite were checked for support.
Abstract
Extrapolation of pharmacokinetic (PK) parameters from in vitro or in vivo animal to human is one of the main tasks in the drug development process. Translational approaches provide evidence for go or no-go decision-making during drug discovery and the development process, and the prediction of human PKs prior to the first-in-human clinical trials. In vitro-in vivo extrapolation and allometric scaling are the choice of method for projection to human situations. Although these methods are useful tools for the estimation of PK parameters, it is a challenge to apply these methods since underlying biochemical, mathematical, physiological, and background knowledge of PKs are required. In addition, it is difficult to select an appropriate methodology depending on the data available. Therefore, this review covers the principles of PK parameters pertaining to the clearance, volume of distribution, elimination half-life, absorption rate constant, and prediction method from the original idea to recently developed models in order to introduce optimal models for the prediction of PK parameters.
Overview
CoChat Summary
## TL;DR
This review summarizes in vitro-in vivo extrapolation (IVIVE) and allometric scaling (AS) approaches for predicting human pharmacokinetic parameters from non-clinical data. It argues that both methods are useful, but accuracy depends heavily on choosing the right model and correction factors such as protein binding, blood flow, and species-specific scaling terms.
## Key findings
- For clearance prediction, AS is “a powerful method” for using non-clinical data, but simple AS alone is often insufficient; the review highlights several refinements such as the rule of exponent (ROE), liver blood flow correction, protein binding correction, QSAR, FCIM, and multiexponential allometric scaling.
- The ROE guidance stated in the paper is: exponent 0.55–0.7 → simple AS; 0.71–1.0 → CL × MLP method; >1.0 → CL × BW method.
- In IVIVE, adding correction factors can improve prediction: Lave et al. reported that correcting clearance with in vitro metabolic rates significantly improved prediction of human CL for 10 extensively metabolized drugs; Chiou et al. reported improved prediction for 15 extensively metabolized drugs when protein binding was considered.
- For volume of distribution, the paper reports that Vd is generally well correlated with body weight, with exponents around 1, usually between 0.8 and 1.1; Mahmood and Balian reported average simple-AS exponents of 0.89 (3 species) and 0.90 (2 species).
## Methods
- Narrative review of methods for predicting human PK parameters from non-clinical data, focused on clearance, volume of distribution, elimination half-life, and absorption-related parameters.
- Synthesizes prior studies using in vitro systems (e.g., human liver microsomes, hepatocytes, recombinant CYP systems) and animal PK data across species for IVIVE and AS.
- Compares empirical and physiologically based analyses, including well-stirred and parallel-tube hepatic clearance models, correction-factor approaches, and multiple AS variants.
## Limitations
- The paper states that IVIVE requires substantial PK knowledge, complex mathematical equations, and is expensive and time-consuming.
- The paper states that AS is empirical and can perform poorly for drugs with high protein binding, extensive active renal secretion, transport processes, or species-specific binding/distribution.
- Evident from the text: this is a review article rather than a new experimental study, so its conclusions depend on the quality and scope of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
5 Valid · 6 Not valid · 80 Not checked · 36 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“One of the main reasons associated with the termination of drug development is inappropriate pharmacokinetic (PK) properties in humans [1].”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 1. Introduction
What the sources say
- Supportedcites [1] Prentis, 1988, Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985), Br. J. Clin. Pharm. source
The Abstract (point 4) states that of 198 NCEs discontinued from further development, 'The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%)'. The Results reinforce this ('the primary cause being inappropriate pharmacokinetics in volunteers (39.4%)' and 'The main reasons for NCEs innovated during the past 20 years being dropped from development were pharmacokinetic difficulties in man or lack of clinical efficacy'). The claim's framing as 'one of the main reasons' matches the source, which is bounded to the 319 NCEs investigated by seven UK-owned companies 1964-1985. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The MA method can successfully predict human clearance.”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 4. Application of AS for the Prediction of Human PK Parameters > 4.2. Prediction of Clearance by AS
What the sources say
- Supportedcites [92] Goteti, 2008, Estimation of human drug clearance using multiexponential techniques, J. Clin. Pharm. source
The Discussion (p. 8) concludes that MA is an improved means of estimating human clearance within acceptable error when preclinical data from more than three species are used. It reports predictions within threefold of measured clearance more than 90% of the time when those species include monkey. This supports the claim that MA can successfully predict human clearance, subject to those conditions. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Their results indicate that monkey is an important species for scaling.”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 4. Application of AS for the Prediction of Human PK Parameters > 4.2. Prediction of Clearance by AS
What the sources say
- Supportedcites [92] Goteti, 2008, Estimation of human drug clearance using multiexponential techniques, J. Clin. Pharm. source
The Discussion (p. 7) explicitly says that analysis of 27 compounds suggested monkey is an important species for interspecies scaling. The Results (p. 6) also report improved human-clearance estimates when monkey was included. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“When the exponent of simple AS was greater than 0.7, MA showed better prediction of human CL than the simple AS method.”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 4. Application of AS for the Prediction of Human PK Parameters > 4.2. Prediction of Clearance by AS
What the sources say
- Supportedcites [92] Goteti, 2008, Estimation of human drug clearance using multiexponential techniques, J. Clin. Pharm. source
The Discussion (p. 8) states that when the simple-allometry slope was greater than 0.7, multiexponential allometry had a clear advantage over simple allometry in predicting human clearance. This analysis concerned 33 of the 50 compounds in data set I. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
In the paper
“Clearance (CL) is considered the most important PK parameter as it is related to drug elimination and bioavailability [27].”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 2. Theoretical Background for the Prediction of Clearance > 2.1. Physiological Clearance Concept
What the sources say
- Not checked — no full text of the sourcecites [27] Zuegge, 2001, Prediction of hepatic metabolic clearance: Comparison and assessment of prediction models, Clin. Pharm. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
72 more claims
Create a free account to see all 127 claims and to verify the 14 references still open.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 31
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“Although issues related to PK and bioavailability have improved since the 2000s [4], nearly half of all the therapeutic candidates in drug development are lost due to poor absorption, distribution, metabolism, excretion (ADME), toxicology, and pharmacology (safety) [5].”
BackgroundPhysiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926 · cited 2×
“44 in humans [35] and CRBC refers to the drug concentration in red blood cells.”
BackgroundResultWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“[87] have suggested a Biopharmaceutics Drug Disposition Classification System (BDDCS), which is modified by the Biopharmaceutics Classification System based on routes of drug elimination and the effect of efflux and absorptive transporters.”
MethodObach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 2×
“Obach [62] has reported the prediction method of human intrinsic hepatic clearance (CLint, H, human) using the in vitro half-life (t1/2) to incorporat non-specific binding factors to microsomes (fu,mic) and/or the fp.”
MethodThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · cited 1×
“Proportionality Vhuman, pred = Vanimal·fu, human fu, animal (95) It is assumed that the volume of distribution at a steady state of free drug is identical between species [120]”
BackgroundUtility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 4×
“Although a CLint, in vitro obtained from dexamethasone-treated microsomes provided an accurate estimate of 77% of the observed CLint, in vivo, the limitation similar to that of Houston [60] persisted.”
BackgroundMethodResultInfluentialPang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Clearance concepts in pharmacokinetics
Rowland, M., Benet, L. Z., & Graham, G. G. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059626 · Cited by 649 · cited 2×
“[34]: CLorg = Q·kel·KP·VE Q + kel·KP·VE (10)”
MethodInterspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648
Research works printed but not linked: 4
- Shargel, L., Andrew, B.C., and Wu-Pong, S. (2016). Applied Biopharmaceutics & Pharmacokinetics, Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division. [7th ed.].
- Weiner, J.G.D. (2016). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press. [5th ed.].
- Carlile, 1997, Scaling factors to relate drug metabolic clearance in hepatic microsome, isolated hepatocytes, and the intact liver, Drug Metab. Dispos., 25, 903
- Kenyon, E.M. (2012). Computational Toxicology: Methods in Molecular Biology, Humana Press.
Cited by
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00352 · Cited by 132
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials
Ozbek, O., Genc, D. E., & Ülgen, K. Ö. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00250 · Cited by 102
“68 The pharmacokinetics of 46, 69, 113, and 162 nm of mesoporous silica NPs was investigated following their intravenous administration to rats.”
New approach methodologies (NAMs) for human-relevant biokinetics predictions
Punt, A., Bouwmeester, H., Blaauboer, B. J., Coecke, S., Hakkert, B., Hendriks, D. F. G., Jennings, P., Kramer, N. I., Neuhoff, S., Masereeuw, R., et al. (2020) · ALTEX · doi:10.14573/altex.2003242 · Cited by 99
“…on the principle of the test, the experimental set-up, the inclusion of reference compounds, the calculation of the in vitro results (correction factors applied or modelling of the in vitro data), and the reporting of the results (Choi et al., 2019; Fisher et al., 2019; Jamei et al., 2009b).”
ResultMurad, N., Pasikanti, K. K., Madej, B. D., Minnich, A., McComas, J., Crouch, S., Polli, J. W., & Weber, A. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000202 · Cited by 62
“Although allometry has some limitations in predicting distribution of highly protein-bound drugs, it has been a valuable technique to predict human PK parameters to determine first-time-in-human dose (Choi et al., 2019).”
MethodYadav, J., Hassani, M. E., Sodhi, J. K., Lauschke, V. M., Hartman, J. H., & Russell, L. E. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1922435 · Cited by 62
“Despite a wealth of in vitro data, predicting in vivo metabolism clearance and transporter-mediated clearance remains complex, often resulting in under-predictions of in vivo clearance (Wood et al. 2017; Chothe et al. 2018; Choi et al. 2019; Liang et al. 2020).”
BackgroundNajjar, A., Punt, A., Wambaugh, J. F., Paini, A., Ellison, C. A., Fragki, S., Bianchi, E., Zhang, F., Westerhout, J., Mueller, D., et al. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03356-5 · Cited by 54
“Technical advancement, particularly the increasing availability of chemical-specific in vitro kinetic data and the in vitro to in vivo scalars for interpreting these data, have also led to this shift towards bottom-up approaches for PBK model development (Choi et al. 2019; Jamei 2016).”
BackgroundMethodJansen, K., Casellas, C. P., Groenink, L., Wever, K. E., & Masereeuw, R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.018 · Cited by 55
Gárate, G., Pascual, J., Pascual-Mato, M., Madera, J., Martín, M. M., & González‐Quintanilla, V. (2024) · The Journal of Headache and Pain · doi:10.1186/s10194-024-01769-4 · Cited by 56
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors
Taylor, A. M., Williams, B. R., Giordanetto, F., Kelley, E. H., Lescarbeau, A., Shortsleeves, K., Tang, Y., Walters, W. P., Arrazate, A., Bowman, C. M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00483 · Cited by 54
Bassani, D., Parrott, N. J., Manevski, N., & Zhang, J. D. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348157 · Cited by 45
Ma, B., Bohnert, T., Otipoby, K. L., Tien, E. S., Arefayene, M., Bai, J., Bajrami, B., Bame, E., Chan, T. R., Humora, M. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00702 · Cited by 40
Gampfer, T. M., Wagmann, L., Park, Y. M., Cannaert, A., Herrmann, J. E., Fischmann, S., Westphal, F., Müller, R., Stove, C. P., & Meyer, M. R. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02726-1 · Cited by 37
Kalam, M. N., Rasool, M. F., Alqahtani, F., Imran, I., Rehman, A. U., & Ahmed, N. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s297981 · Cited by 32
Petersson, C., Zhou, X., Berghausen, J., Cebrián, D. Á., Davies, M., DeMent, K., Eddershaw, P. J., Riedmaier, A. E., Leblanc, A. F., Manveski, N., et al. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00735-9 · Cited by 27
Peng, J., Ladumor, M. K., & Unadkat, J. D. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000557 · Cited by 31
“First, CLrenal,B in both non-pregnant and pregnant women were estimated (if not already stated in the publications) using equations (1) - (4) (Cho et al., 2019).”
BackgroundLong-acting injectable donepezil microspheres: Formulation development and evaluation
Choi, G.-W., Lee, S., Kang, D. W., Kim, J. H., Kim, J. H., & Cho, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.022 · Cited by 30
Self-citationJeong, S., Jang, J.-H., Cho, H., & Lee, Y. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03328-9 · Cited by 24
Self-citationAntiparasitic Effects of Sulfated Polysaccharides from Marine Hydrobionts
Besednova, N. N., Zaporozhets, T. S., Andryukov, B. G., Kryzhanovsky, S. P., Ermakova, S. P., Kuznetsova, T. A., Voronova, A. N., & Shchelkanov, M. Y. (2021) · Marine Drugs · doi:10.3390/md19110637 · Cited by 23
Carvalho, A. M., Fernandes, E., Gonçalves, H., Giner-Casares, J. J., Bernstorff, S., Nieder, J. B., Oliveira, M. E. C. D. R., & Lúcio, M. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119222 · Cited by 20
Seo, S., Han, D., Choi, E., Park, T., Byun, J. H., Cho, H., Jung, I. H., & Yoon, I. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112520 · Cited by 20
Self-citationAlmeida, A., Fernandes, E., Sarmento, B. F. C. C., & Lúcio, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060869 · Cited by 18
“These predictions can be further improved by considering in vitro data and binding of drugs to plasma proteins [34,44-46].”
BackgroundMethodWang, Z., & Chan, E. C. Y. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000928 · Cited by 14
Shriya, V. A., Nayak, U. Y., Sathyanarayana, M. B., Chaudhari, B. B., & Bhat, K. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03093-9 · Cited by 20
Witta, S., Collins, K. P., Ramirez, D. A., et al. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1052 · Cited by 13
Wu, N., & An, G. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00481-w · Cited by 11
“25 was used for the absorption rate constant (38,39).”
MethodFurther Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy
Williamson, B., Colclough, N., Fretland, A. J., Jones, B., Jones, R. D. O., & McGinnity, D. F. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200312104837 · Cited by 10
Liang, X., & Lai, Y. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1912012 · Cited by 11
“dispersion liver models [24], the assumption of rapidequilibrium does not always hold true when the free per-”
BackgroundPonraj, K., Gaither, K. A., Singh, D. K., Davydova, N. Y., Zhao, M., Luo, S., Lazarus, P., Prasad, B., & Davydov, D. R. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116569 · Cited by 7
MMPK: A Multimodal Deep Learning Framework to Predict Human Oral Pharmacokinetic Parameters
Li, X., Zhan, M., Fang, J., Liu, G., Tang, Y., & Li, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01522 · Cited by 11
Desai, J. M., Karve, A. S., Gudelsky, G. A., Gawali, M. V., Seibel, W. L., Sallans, L., Dasgupta, B., & Desai, P. B. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01278-8 · Cited by 12
Evolution of human pharmacokinetics prediction methods: from allometry to artificial intelligence
Choi, N., Shin, B. S., & Shin, S. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00805-6 · Cited by 11
“…mostly within a twofold range of the observed data across administration where Q H is hepatic blood flow (blood basis), f B is the unbound fraction in blood, and CL int represents the scaled intrinsic clearance derived from microsomal or hepatocyte assays (Choi et al. 2019 ; Rowland and Pang 2022).”
Prediction of Drug Clearance from Enzyme and Transporter Kinetics
Kulkarni, P., Youssef, A. S., & Argikar, A. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_14 · Cited by 7
Tuet, W. Y., Pierce, S. A., Conroy, M., Vignola, J. N., Tressler, J., diTargiani, R. C., McCranor, B. J., & Wong, B. J. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1000 · Cited by 5
Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy
Choules, M. P., Bonate, P. L., Heo, N., & Weddell, J. C. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09889-1 · Cited by 9
Barbetta, M. F. S., Brambilla, T. H. B., Perovani, Í. S., et al. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116957 · Cited by 6
Assessment of Cytochrome P450 Metabolic Clearance Using Hepatocyte Suspension
Cai, J., & Shalan, H. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1542-3_15 · Cited by 6
Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator
Li, X., Zhang, Z., Chen, Y., Wang, B., Yang, G., Xiangbin, X., Yechao, B., Bai, D., Feng, B., Mao, Y., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00002 · Cited by 6
Lee, S. J., Bae, S. H., Jeon, S., Ji, H. Y., & Han, S. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15891 · Cited by 6
“…bioavailability (F) in humans, we calculated the fraction absorbed from the gut lumen to enterocytes (F a ) and the fraction escaping hepatic first-pass metabolism (F h ) and assumed that the fraction escaping the gut wall first-pass metabolism (F g ) is equal to 1 21 (Equation [3], [6] and [7]).”
BackgroundMethodPrediction method of pharmacokinetic parameters of small molecule drugs based on GCN network model
Yang, Z., Wang, Y., Du, G., Zhan, Y., & Zhan, W. (2024) · Journal of Molecular Modeling · doi:10.1007/s00894-024-06051-7 · Cited by 5
“Although this method can achieve the goal of measuring the effectiveness of drugs, using physiological experimental measurements not only consumes a lot of resources but also has the problem of errors caused by factors such as sampling points [6].”
Calemi, D. B. D. A., Godoi, A. B., Minuti, G., Neto, F. C., Hispagnol, G. F., Pilon, A. C., Costa, J. L., Hyslop, S., & Antunes, N. D. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050601 · Cited by 5
“In vitro t 1/2 was calculated using to the following equation [60,61]: where k is the slope of the log-linear regression graph of the percentage of drug remaining as a function of time.”
Kang, D. W., Kim, J. H., Choi, G.-W., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03828-w · Cited by 5
“…k a ) in the human PBPK model of NDMA were extrapolated from the rat parameters estimated in our previous study by following equations (Kenyon 2012; Cho et al. 2019; Kang et al. 2024) where k is the first-order rate constants, CL is the clearance, V max is the maximum metabolic rate, and BW is…”
Self-citationPunt, A., Bos, P., Hakkert, B., & Louisse, J. (2022) · ALTEX · doi:10.14573/altex.2202131 · Cited by 9
“Therefore, data obtained with the different test systems need to be integrated, for example by PBK modelling (Louisse et al., 2017; Bessems et al., 2014; Choi et al., 2019), while taking the uptake and kinetics of various ports of entry (oral, dermal and inhalation) into account.”
MethodZimmer, A., & Collier, A. C. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2462527 · Cited by 4
“For example, studies interested in exploring hepatic intrinsic clearance utilize hepatocellularity per gram liver (HPGl) as the scaling factor of choice (Houston 1994). likewise, studies utilizing recombinant human cytochrome P450 utilize scaling factors, such as the relative expression factor (ReF) and relative activ…”
InfluentialAntunes, N. D. J., Moreira, F. D. L., Kipper, K., et al. (2022) · Pharmaceuticals · doi:10.3390/ph16010028 · Cited by 4
Kang, D. W., Kim, J. H., & Cho, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122510 · Cited by 6
Self-citationDetermination of human FaFg of polyphenols using allometric scaling
Kikuchi, T., Shigemura, S., Ito, Y., & Saito, K. (2022) · The Journal of Toxicological Sciences · doi:10.2131/jts.47.409 · Cited by 5
Bharti, K., Deepika, D., Kumar, M., et al. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02680-y · Cited by 4
“Allometric scaling was applied to scale biochemical parameters from rat to human [51, 52].”
MethodRamisetty, B. S., Yang, S., Dorlo, T. P. C., & Wang, M. Z. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00328-24 · Cited by 3
Wu, X., Wu, P.-Y., Chou, W., Tell, L. A., & Lin, Z. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01170-2 · Cited by 3
“Although in vitro to in vivo extrapolation (IVIVE) and allometric scaling (AS) are commonly used to estimate PK parameter values (6), these traditional approaches have some weaknesses as they are costly and time-consuming.”
Pereira, G. R. C., Viana, G. M., Huber, M. B., Rodrigues, P. S., Gonçalves, A. R. S. D. P., Sathler, P. C., Rodrigues, C. R., Abrahim-Vieira, B. D. A., & Cabral, L. M. (2026) · ACS Omega · doi:10.1021/acsomega.5c12576 · Cited by 2
Choi, S., Han, S., Lee, S. J., Lim, B., Bae, S. H., Han, S., & Yim, D. (2022) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2022.106662 · Cited by 3
Noorlander, A., Fabian, E. J., van Ravenzwaay, B., & Rietjens, I. M. C. M. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02908-x · Cited by 2
“When using in vitro models for biliary excretion, important challenges relate to the type of in vitro model to be used and the subsequent translation of the in vitro data to the in vivo situation using adequate scaling factors (Choi et al. 2019).”
MethodPreclinical Data Extrapolation to Clinical Reality: A Translational Approach
Varshney, P. K., & Chandra, P. (2024) · Current Drug Discovery Technologies · doi:10.2174/0115701638302778240417045451 · Cited by 1
Zhu, X., Kong, W., Wang, Z., Liu, X., & Liu, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121596 · Cited by 1
Xu, W., Pan, C., He, Q., Zhu, X., & Xiang, X. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00443-4 · Cited by 1
Misconceptions among medicinal chemists regarding ADME and PK optimization
Pan, Y. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03543-4 · Cited by 1
Cao, X., Xiao, J., Lei, Y., Zhong, Y., Hu, L., Li, X.-S., Liang, M.-D., Chen, K., & Bai, W.-B. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116092 · Cited by 1
Exposure Measurements on Biomimetic Lobules Using Virtual Experiments to Help Improve IVIVE
Krishnan, P., Dutta, L., Smith, A., et al. (2020) · EPiC series in computing · doi:10.29007/hjfc
“Predicting the hepatic clearance of new chemical entities is accomplished most frequently using in vitro-in vivo extrapolation (IVIVE) methods provide a comprehensive review [1].”
BackgroundOn chip complex breast tumour microenvironment: application to research in nanomedicine
Blondé, J.-B. (2020) · doi:10.3990/1.9789036550598 · Cited by 1
Jansen, K. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/663
In vitro hepatic metabolism of curcumin diethyl disuccinate in different animal species
Jithavech, P., & Rojsitthisak, P. (2019) · Chula Digiverse · doi:10.58837/chula.the.2019.408
Zaher, H., & Zhang, G. (2023) · Wiley eBooks · doi:10.1002/9781119660699.ch39
Quantitative extrapolation interspecies scaling/low-dose extrapolation
Otavi, S., Gupta, T., Tekade, M., Singh, A., Sengupta, P., Agrawal, A., & Tekade, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15842-1.00011-9 · Cited by 1
Kim, J. H., Hong, Y. B., Kang, D. W., et al. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00683-w
Self-citationHidayati, N. R., Nuraeni, N., Hardiansyah, D., & Pawiro, S. A. (2024) · AIP conference proceedings · doi:10.1063/5.0228110 · Cited by 1
Zhong, L., Li, L., He, Q., Zhu, X., Xiang, P., Xiang, X., & Yan, H. F. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117352 · Cited by 1
PKPD modeling and in silico models
Pehrson, R., Winiwarter, S., Subramanian, V., Mogemark, M., & Miljković, F. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00022-4
Bae, S. H., Park, S. Y., Choi, H. G., & Kim, S. H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070914
Soliman, M., Mostafa, N. S., Mahmoud, S. T., El‐Gamil, D. S., Abdel‐Halim, M., & Fouad, M. M. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124888
Ockhuijsen, L., Ragas, A. M. J., & Hendriks, A. J. (2025) · Toxicology · doi:10.1016/j.tox.2025.154377
In vitro hepatic metabolism and associated binding of enniatin B
Hégarat, L. L., Dubreil, E., Yondre, N. L., Martin, S., Brée, F., & Henri, J. (2026) · Toxicology · doi:10.1016/j.tox.2025.154379
Dias, B. B., Olivo, L. B., & de Araújo, B. V. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70165
Zhang, M., Cremers, T. I. F. H., Rottschäfer, V., & de Lange, E. C. M. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70788
Metadata
- Authors
- Choi, G.-W., Lee, Y.-B., & Cho, H.-Y.
- Affiliations
- CHA University (KR)
- Chonnam National University (KR)
- Corresponding author
- Cho, Hea-Young
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-04-05
- Volume
- 11
- Issue
- 4
- Pages
- 168
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC6523982
- OpenAlex
- W2930584951
- Cited by
- 79
- References
- 143
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 14 · 2023: 7 · 2022: 14 · 2021: 11 · 2020: 12 · 2019: 1
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- in vitro-in vivo extrapolation, allometric scaling, human pharmacokinetic prediction, drug development, clearance, volume of distribution, elimination half-life, absorption rate constant, translational toxicology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.